Revenue from Mepha will help Cephalon counter a sales decline after its top product, the sleep-disorder drug Provigil, loses patent protection in 2012. ...
Cephalon's biggest seller, Provigil, will face its own generic competition in 2012. Baldino said the deal represents an "excellent strategic fit" with a ...
The firm said, "The key driver for the EPS change is the 29% Provigil price increase in Nov. We believe that the recent positive move in the stock has been ...
Email this story